Durga Borkar, MD, sat down with Sydney Crago of Modern Retina to discuss one of her presentations on the first time phase 2 clinical trial results for ONL-1204 for rhegmatogenous retinal detachment from the Retina Society meeting being held this year in Lisbon, Portugal.
Durga Borkar, MD, sat down with Sydney Crago of Modern Retina to discuss one of her presentations on the 12-month outcomes of the FARETINA and FARWIDE studies from the Retina Society meeting being held this year in Lisbon, Portugal.
According to the company, the pilot study showed procedural feasibility of ophthalmic artery angioplasty in the treatment of vascular lesions associated with geographic atrophy (GA).
This Week in Ophthalmology is a video series highlighting some of the top articles featured on the Ophthalmology Times website.
Visual acuity and macular anatomy were maintained, with some changes in fluid management.
According to research conducted by investigators at the Perelman School of Medicine at the University of Pennsylvania School of Medicine, patients with a rare inherited disease affecting their sight experienced quick vision improvements that sustained for the full year-long study.
CHG is an effective alternative antiseptic to PI and the cost is outweighed by increased patient comfort.
Results showed that patients who received veligrotug, an intravenously delivered anti-insulin-like growth factor-1 receptor (IGF-1R) antibody, had “statistically significant and clinically meaningful improvements across [multiple] key disease endpoints at the primary efficacy analysis timepoint of 15 weeks.”
In a presentation at the Retina Society meeting in Lisbon, Portugal, Ivana Kim, MD, explained that AU-011 (Bel-Sar) demonstrated 80% tumor control rate, 90% visual acuity preservation, and a favorable safety profile.
Jennifer Lim, MD, FARVO, FASRS, discusses her presentation on differential artery-vein analysis and how it improves OCTA performance for AI classification of diabetic retinopathy at the annual Retina Society meeting being held this year in Lisbon, Portugal.
Aflibercept biosimilars have cleared several hurdles on their way to marketplace
Theodore Leng, MD, MS, sat down with David Hutton of Ophthalmology Times to discuss his presentation on Progression of Newly Diagnosed Geographic Atrophy: An Observational, Retrospective US-based Cohort Study at the annual Retina Society meeting being held this year in Lisbon, Portugal
According to the organization, the map and report provide public, professionals and decisionmakers with data on children’s vision issues at the county and state level.
The companies’ eye care line will feature refreshed design and improved packaging for Ocucyn Eyelid and Eyelash Cleanser. The full line will be introduced at the American Academy of Ophthalmology's annual meeting in Chicago.
Prem Subramanian, MD, PhD, a professor of ophthalmology at the Sue Anschutz-Rodgers Eye Center, will use high-tech ocular equipment to monitor the four-member Polaris Dawn crew to investigate why eyes change in space.
Push to identify biomarkers for earlier diagnosis, new therapeutic targets.
Researchers from NYU Langone published a study reporting on the eye's functioning, without sight but offering hope for the future.
Lynn Hassman, MD, PhD, has received the Philip and Elaine Ellis New Investigator in Ophthalmology Research Award, and will focus on seeking treatment options for uveitis patients.
The Retina Society meeting will take place in Lisbon, Portugal from September 11-15, 2024.
Identifying all genetic culprits may improve diagnostics and prognoses.
Research by investigators at Trinity College in Dublin shows how the gene therapy conferred significant benefit in animal models, and in human cells derived from people with glaucoma.
Sujay Jadhav, CEO of Verana Health, a digital health company dedicated to revolutionizing patient care and clinical research through real-world data (RWD), provides an overview of new FDA guidance.
APP13007, according to the company, is the first product developed using Formosa’s proprietary APNT nanoparticle formulation platform.
The contract research organization and technology solution is for the execution of ophthalmology clinical trials.
This Week in Ophthalmology is a video series highlighting some of the top articles featured on the Ophthalmology Times website.
The FDA and Palatin agreed on a clear regulatory path for PL9643 NDA submission in DED. The company hopes to start patient enrollment to start in 4Q calendar year 2024. Topline results currently are expected in late 2025
In the case study, a 63-year-old patient presented with severe acute pain in the right eye, which was diagnosed as a pupillary block leading to acute angle closure glaucoma.
BI 771716, with technology licensed from CDR-Life, is a highly specific antibody fragment, possibly enabling an optimized penetration through all retinal layers to the most critical target site driving GA disease pathology.
MK-3000, formally known as EYE103, is an investigational, potentially first-in-class tetravalent, tri-specific antibody that acts as an agonist of the Wnt signaling pathway.
.png "Optometry Times"){kind=logo}
